Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
← catalyst calendarSponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
8actual
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This study was prematurely terminated due to sponsor decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-12 | actual | When the study began enrolling |
| Primary completion | 2025-11-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-12 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
Intervention
- Drug: NBI-921352
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs
measured Day 1 to Week 168
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed